Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.
More...
Linear Mode
